Search Results for keywords:"Drug Enforcement Administration"

The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration of James T. Craig, D.D.S., a dentist from Colorado, meaning he can no longer handle controlled substances. This decision was made because his dental license in Colorado was revoked, and he lacked the necessary state authority to dispense controlled substances. The DEA notified Craig of his right to a hearing, which he opted not to request, resulting in an automatic admission of the allegations against him. Consequently, any pending applications from Craig to renew or modify his registration have also been denied.

Janssen Pharmaceuticals Inc. has filed an application with the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances for analytical purposes. Public comments or objections regarding this application are accepted until March 17, 2025. Hearings can also be requested by this date. Comments should be submitted via the Federal eRulemaking Portal, and requests for hearings must be sent to the DEA at specified addresses.

Groff Health, Inc. has applied to the Drug Enforcement Administration to become a bulk manufacturer of certain controlled substances. People can submit electronic comments or objections regarding this application by March 24, 2025. Comments must be submitted through the Federal eRulemaking Portal, and commenters will receive a tracking number to confirm successful submission. The company plans to produce these substances for internal use or sale but is not authorized for other activities related to these drug codes.

The Drug Enforcement Administration (DEA) has announced that Ohana Bio Pharma, LLC has applied to be registered as a bulk manufacturer of controlled substances in schedule I, specifically for marihuana. This application is part of a program to grow marihuana for scientific and medical research. The DEA will evaluate the application according to its regulations to ensure legal compliance and prevent any misuse. Interested parties can submit their comments or objections by May 27, 2025, through the Federal eRulemaking Portal.

Globyz Pharma, LLC has applied to the Drug Enforcement Administration (DEA) for registration as an importer of controlled substances for analytical testing. The application does not authorize any other activities, such as importing FDA-approved finished dosage forms for sale. Interested parties, including registered manufacturers, can submit comments or objections, or request a hearing regarding this application by March 26, 2021. The DEA's decision will be based on alignment with legal requirements under 21 U.S.C. 952(a)(2).

S&B Pharma LLC, also known as Norac Pharma, has submitted an application to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company plans to import these substances in bulk to manufacture other controlled drugs for its customers. The public can submit comments or request a hearing regarding this application until February 11, 2021. All submissions should be sent to the DEA offices in Springfield, Virginia.

Sigma Aldrich Co. LLC. has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances, specifically for drug testing and analysis in research facilities. The application was submitted on January 15, 2021. Public comments or objections regarding this proposed registration are invited until March 18, 2021. The company plans to import synthetic Tetrahydrocannabinols; however, their registration does not authorize them to import finished drug products for commercial sale.

The Drug Enforcement Administration (DEA) has decided to revoke John Stanton, M.D.'s DEA registration because his medical license in Tennessee was revoked, meaning he can't legally handle controlled substances in the state. An Order to Show Cause was issued previously, suggesting the removal of his DEA Certificate of Registration, as he didn't request a hearing, leading to a default judgment. As a result, the DEA has also denied Dr. Stanton's pending applications for any new registration in Tennessee. This decision was signed by the Acting Administrator of the DEA and will take effect on May 21, 2025.

IsoSciences, LLC has applied to the Drug Enforcement Administration to become a bulk manufacturer of certain controlled substances. They plan to create synthetic versions of Marihuana and Tetrahydrocannabinols for use in analytical testing, and no other activities for these drugs are permitted with this registration. The public has until March 15, 2021, to submit written comments or objections, or to request a hearing regarding this application.

Noramco has submitted an application to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company specifically plans to produce active pharmaceutical ingredients, including synthetic marihuana and tetrahydrocannabinols. Individuals or organizations can submit comments or objections to this application by March 25, 2025, through the Federal eRulemaking Portal. The announcement provides further details about the application and the procedures for submitting feedback.